AR035875A1 - Composicion farmaceutica estable de inhibidores de reductasa hmg-coa, y una tableta para la administracion oral - Google Patents
Composicion farmaceutica estable de inhibidores de reductasa hmg-coa, y una tableta para la administracion oralInfo
- Publication number
- AR035875A1 AR035875A1 ARP020101607A ARP020101607A AR035875A1 AR 035875 A1 AR035875 A1 AR 035875A1 AR P020101607 A ARP020101607 A AR P020101607A AR P020101607 A ARP020101607 A AR P020101607A AR 035875 A1 AR035875 A1 AR 035875A1
- Authority
- AR
- Argentina
- Prior art keywords
- hmg
- coa reductase
- pharmaceutical composition
- oral administration
- reductase inhibitors
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title abstract 2
- 150000002337 glycosamines Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003002 pH adjusting agent Substances 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 abstract 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 abstract 1
- 159000000000 sodium salts Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición farmacéutica que comprende, como un ingrediente activo, un inhibidor de HMG-CoA-reductasa; donde esta composición comprende un aminoazúcar, con la condición de que se excluyan las composiciones: que comprendan deshidroepiandrosterona (DHEA), un agente descamante seleccionado a partir de retinoides, derivados de ácido salicílico acilados, o inhibidores de HMG-CoA-reductasa, y derivados de azúcar; y que comprenden gérmenes para una materia prima de fabricación de koji, y monacolina K. Una tableta para administración oral, que consiste en pravastatina en la forma de una sal sódica, uno o más de relleno, aglutinante, desintegrante, y/o lubricante, y un aminoazúcar como un agente de ajuste del pH (basificante), en una cantidad tal que una dispersión de la tableta en agua tenga un pH de 7.0 a 8.7.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0111077.4A GB0111077D0 (en) | 2001-05-04 | 2001-05-04 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035875A1 true AR035875A1 (es) | 2004-07-21 |
Family
ID=9914116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101607A AR035875A1 (es) | 2001-05-04 | 2002-05-02 | Composicion farmaceutica estable de inhibidores de reductasa hmg-coa, y una tableta para la administracion oral |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6911472B2 (es) |
| EP (1) | EP1392277A2 (es) |
| AR (1) | AR035875A1 (es) |
| AU (1) | AU2002310798A1 (es) |
| GB (1) | GB0111077D0 (es) |
| TW (1) | TWI239839B (es) |
| WO (1) | WO2002089788A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| EP1404303A4 (en) * | 2001-06-21 | 2006-03-15 | Andrx Pharmaceuticals Inc | STABLE PHARMACEUTICAL COMPOSITIONS BASED ON PRAVASTATIN |
| MXPA03010266A (es) | 2001-06-29 | 2004-03-10 | Warner Lambert Co | Formas cristalinas de la sal de calcio del acido [r-(r*, r*)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin). |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| EP2540704B1 (en) | 2004-05-05 | 2019-07-03 | Pfizer Products Inc. | Benethamine salt forms of atorvastatin |
| WO2006006021A2 (en) * | 2004-06-28 | 2006-01-19 | Glenmark Pharmaceuticals Limited | Stabilized pharmaceutical compositions of preferably a statin |
| AU2005305460B2 (en) | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| GB0516604D0 (en) * | 2005-08-12 | 2005-09-21 | Sandoz Ag | Rapidly dispersing/disintegrating compositions |
| EP1968593B1 (en) * | 2005-12-20 | 2017-08-23 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid |
| HU227610B1 (en) * | 2006-09-18 | 2011-09-28 | Richter Gedeon Nyrt | Pharmaceutical compositions containing rosuvastatin potassium |
| DE102007007865A1 (de) | 2007-02-14 | 2008-08-21 | Jennissen, Herbert, Prof. Dr. | Verfahren zur Herstellung von lagerfähigen Implantaten mit einer ultrahydrophilen Oberfläche |
| CZ300047B6 (cs) * | 2007-03-02 | 2009-01-21 | Zentiva, A. S. | Farmaceutická kompozice s obsahem úcinné látky atorvastatinu |
| US20090069623A1 (en) * | 2007-08-21 | 2009-03-12 | Virginia Commonwealth University Intellectual Property Foundation | Methods and compositions for treatment or prevention of radiation-induced fibrosis |
| MX344885B (es) * | 2008-11-10 | 2017-01-10 | Psicofarma S A De C V | Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido. |
| UA108742C2 (uk) | 2009-09-23 | 2015-06-10 | Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1 | |
| KR101298788B1 (ko) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | 안정성이 개선된 복합제제 |
| TWI636783B (zh) * | 2012-04-18 | 2018-10-01 | 友霖生技醫藥股份有限公司 | 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物 |
| CN108118042B (zh) * | 2016-11-30 | 2021-01-15 | 中国科学院青岛生物能源与过程研究所 | 2-甲基丁酸侧链水解酶和产莫纳可林j的曲霉菌株及其构建方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| DE69324504T2 (de) | 1993-01-19 | 1999-08-26 | Warner-Lambert Co. | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| US6551617B1 (en) * | 2000-04-20 | 2003-04-22 | Bristol-Myers Squibb Company | Taste masking coating composition |
| WO2001093860A1 (en) * | 2000-06-09 | 2001-12-13 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
-
2001
- 2001-05-04 GB GBGB0111077.4A patent/GB0111077D0/en not_active Ceased
-
2002
- 2002-05-02 TW TW091109135A patent/TWI239839B/zh not_active IP Right Cessation
- 2002-05-02 AR ARP020101607A patent/AR035875A1/es unknown
- 2002-05-03 WO PCT/EP2002/004891 patent/WO2002089788A2/en not_active Ceased
- 2002-05-03 AU AU2002310798A patent/AU2002310798A1/en not_active Abandoned
- 2002-05-03 US US10/476,816 patent/US6911472B2/en not_active Expired - Fee Related
- 2002-05-03 EP EP02735331A patent/EP1392277A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002089788A3 (en) | 2002-12-12 |
| US20040167085A1 (en) | 2004-08-26 |
| AU2002310798A1 (en) | 2002-11-18 |
| TWI239839B (en) | 2005-09-21 |
| WO2002089788A2 (en) | 2002-11-14 |
| GB0111077D0 (en) | 2001-06-27 |
| EP1392277A2 (en) | 2004-03-03 |
| US6911472B2 (en) | 2005-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035875A1 (es) | Composicion farmaceutica estable de inhibidores de reductasa hmg-coa, y una tableta para la administracion oral | |
| DE602007004618D1 (de) | Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren | |
| TW200630123A (en) | Oral medicinal product with modified release of at least one active principle in multimicrocapsular form | |
| IL184898A0 (en) | Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same | |
| MX2009005308A (es) | Composiciones que comprenden peroxido de benzoilo, al menos un derivado del acido naftoico y al menos un compuesto del tipo polimeros de poliuretano o derivados de estos y sus usos. | |
| NO20074703L (no) | Antibakterielle piperidinderivater | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| SG161256A1 (en) | Oral pharmaceutical formulations comprising fenofibric acid and/or its salts | |
| NO20080220L (no) | Formuleringer med hoy medikament belastning og doseringsformer | |
| MX2012002785A (es) | Derivado de indenona y composicion farmaceutica que comprende el mismo. | |
| TW200800931A (en) | Novel piperazines as antimalarial agents | |
| TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
| TW200744672A (en) | Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily | |
| WO2010075287A3 (en) | Compounds and methods for the treatment of pain and other diseases | |
| PL1638582T3 (pl) | Zastosowanie kwasu hialuronowego do wytwarzania środków do leczenia nawracających aft w jamie ustnej | |
| TNSN07203A1 (en) | Pharmaceutical compositions for the treatment of cellulite | |
| IL191670A0 (en) | Compounds for the inhibition of apoptosis | |
| WO2006108680A3 (en) | Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against protozoa and helminthes | |
| PL1893237T3 (pl) | Kompozycja farmaceutyczna zawierająca elastomer poliorganosiloksanowy i solubilizowany składnik aktywny | |
| AR023219A1 (es) | Combinacion de inhibidor(es) de no-sintasa y antioxidante(s) metabolico(s) | |
| GB0327390D0 (en) | Pharmaceutical formulations | |
| WO2006103119A3 (en) | Tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics | |
| MX2008006476A (es) | Composiciones de lipopeptidos. | |
| TW200716114A (en) | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof | |
| WO2007039821A3 (en) | Novel inhibitors of tyrosinase, their method of preparation and their use in human medicine and in cosmetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |